A5051511805- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Immune cells in cancer
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Cancer, Hypoxia, and Metabolism
- vaccines and immunoinformatics approaches
- Lung Cancer Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- T-cell and B-cell Immunology
- Phagocytosis and Immune Regulation
- Reproductive System and Pregnancy
- Inflammation biomarkers and pathways
- Virus-based gene therapy research
- BRCA gene mutations in cancer
- Cell death mechanisms and regulation
- Microtubule and mitosis dynamics
- Nanoplatforms for cancer theranostics
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Atherosclerosis and Cardiovascular Diseases
- Chemokine receptors and signaling
- Cellular Mechanics and Interactions
University of Crete
2015-2024
Senologic Hellenic Society
2019
Hellenic Oncology Research Group
2018
Translational Research in Oncology
2016
University Hospital of Heraklion
2007
University of Patras
2007
Vaxon Biotech (France)
2006
Genopole (France)
2006
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of with immunosuppressive properties and might confer to worse prognosis in cancer patients. The presence phenotypically newly described subpopulations MDSCs their association the clinical outcome were investigated non-small cell lung (NSCLC) percentages correlation between distinct immune peripheral blood 110 chemotherapy-naive patients before treatment healthy controls using flow cytometry. Two monocytic [CD14 +...
Abstract The role of the different circulating regulatory T-cells (Treg) subsets, as well their correlation with clinical outcome non-small cell lung cancer (NSCLC) patients is poorly understood. Peripheral blood from 156 stage III/IV chemotherapy-naive NSCLC and 31 healthy donors (HD) was analyzed flow cytometry for presence functionality CD4 + Treg subsets (naive, effector terminal effector). Their frequencies were correlated outcome. All exhibited highly suppressive activity by TGF-β...
To evaluate the immunological and clinical response as well safety of optimized peptide telomerase reverse transcriptase p572Y (TERT572Y) presented by HLA-A*0201 in patients with advanced non-small-cell lung cancer (NSCLC).Twenty-two NSCLC residual (n = 8) or progressive disease (PD; n 14) following chemotherapy and/or radiotherapy received two subcutaneous injections TERT572Y followed four native TERT572 administered every 3 weeks. Peptide-specific immune responses were monitored...
Circulating tumor cells (CTCs) could escape from the immune system through programmed death-ligand 1 (PD-L1)/programmed cell death protein (PD-1) axis leading to development of metastasis. The current study investigated expression PD-1/PD-L1 on CTCs isolated non-small lung cancer (NSCLC) patients treated with chemotherapy.CTCs were 30 chemo-naïve stage IV NSCLC before and after front-line chemotherapy using ISET filtration platform. detected by Giemsa immunofluorescence (IF) staining....
The role of CD47 and PD-L1 expression on circulating tumor cells (CTCs) remains unclear, it is currently unknown whether their distribution varies between the blood tissue in breast cancer (BC). In this study, was investigated a) peripheral mononuclear cell (PBMC) cytospins from early (n = 100) metastatic 98) BC patients, by triple immunofluorescence for CD47/PD-L1/Cytokeratins, b) matched primary and/or CTC-positive patients using immunohistochemistry. CD47+and/orPD-L1+ CTCs were detected...
The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small lung cancer (NSCLC) to serve as a tool investigation immune checkpoints real time. Different approaches—ficoll density, erythrolysis, their combination with magnetic separation, ISET, and Parsortix—were compared spiking experiments using A549, H1975, SKMES-1 NSCLC lines. most efficient methods were tested patients (n = 15) receiving immunotherapy...
Abstract Immune checkpoint inhibitors (ICI), which target immune regulatory pathways to unleash antitumor responses, have revolutionized cancer immunotherapy. Despite the remarkable success of ICI immunotherapy, a significant proportion patients whose tumors respond these treatments develop immune-related adverse events (irAE) resembling autoimmune diseases. Although clinical spectrum irAEs is well characterized, their successful management remains empiric. This in part because pathogenic...
Circulating tumor cells (CTCs) are the major players in metastatic process. A potential mechanism of cell migration and invasion is formation microtentacles cells. These structures supported by α-tubulin (TUB), detyrosinated (GLU), vimentin (VIM). In current study, we evaluated expression those cytoskeletal proteins CTCs. Forty patients with breast cancer (BC) (16 early 24 metastatic) were enrolled study. CTCs isolated using ISET platform stained following combinations antibodies:...
TLR4 and pSTAT3 are key players in cancer inflammation immune evasion; however, their role the peripheral blood (PB) is largely unexplored. Herein we evaluated expression circulating tumor cells (CTCs) peripheral-blood mononuclear (PBMCs) of patients with early (n = 99) metastatic 100) breast (BC). PB samples obtained prior to adjuvant first-line therapy, were immunofluorescently stained for Cytokeratins/TLR4/pSTAT3/DAPI analyzed via Ariol microscopy. TLR4+ CTCs detected 50% 68% CTC-positive...
Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes different immunosuppressive in peripheral blood of patients with metastatic breast (mBC). Materials Methods: Blood was obtained from 38 pre-treated mBC before a new line treatment. CTC detection characterization performed by triple immunofluorescent staining, while Myeloid-derived Suppressor Cells (MDSCs) T regulatory (Tregs) were...
Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation between levels of PD-1+ and PD-L1+-expressing (ICs) circulating (CTCs) patients with non-small lung cancer (NSCLC).Peripheral blood obtained 37 chemotherapy-naïve metastatic NSCLC before treatment. PD-1 PD-L1 expression evaluated (1) on ICs anti-tumor function (CD4+ CD8+ T-cells, B-cells,...
Abstract Background: The activation of Fas (CD95/APO-1) death receptor by ligand (FasL/CD95L) can trigger a signal transduction pathway leading to apoptosis, which is common used immune cells for tumor elimination. Cancer also exploit FasL expression induce cell known as "Fas counterattack", and thus increase their invasion migration capacity. We herein assessed the on circulating (CTCs) in peripheral blood (PB) patients with metastatic BC. Methods: PB was obtained from 98 BC at baseline...
The Fas/Fas ligand (FasL) system is a major apoptosis-regulating pathway with key role in tumor immune surveillance and metastasis. expression of Fas/FasL on mammary tissues holds prognostic value for breast cancer (BC) patients. We herein assessed circulating cells (CTCs) matched peripheral blood mononuclear (PBMCs) from 98 patients metastatic BC receiving first-line treatment. Fas+, FasL+, Fas+/FasL+ CTCs were identified 88.5%, 92.3%, 84.6% CTC-positive patients, respectively. In addition,...
The aim of this study was to investigate the best administration telomerase reverse transcriptase (TERT572), an human leukocyte antigen-A*0201-restricted cryptic epitope telomerase, and its optimized variant TERT572Y elicit specific T cell immune responses in cancer patients. Forty-eight patients with chemo-resistant tumors received 2 subcutaneous injections at mg followed random by 4 either TERT572 or peptides every 3 weeks. Specific response evaluated interferon-γ enzyme-linked...
Abstract Background: The detection of circulating tumor cells (CTCs) in peripheral blood (PB) breast cancer (BC) patients is an unfavourable prognostic factor; however further characterization these required to understand their biological role. presence stemness and epithelial-to-mesenchymal transition (EMT) markers CTCs could be important marker enhanced metastatic capacity. On the other hand, myeloid-derived suppressor (MDSCs) T regulatory (Tregs) play essential role tumor-immune evasion,...
e14045 Background: CTCs expressing innate (CD47) and adaptive (PD-L1) immune checkpoints may have enhanced potential to escape immunosurveillance. In the current study, we evaluated incidence clinical relevance of CD47 and/or PD-L1 in patients with mBC. Methods: Blood was obtained from 98 mBC before initiation first-line therapy. Triple immunofluorescence staining for cytokeratins (CK), performed on peripheral blood mononuclear cells (PBMC) cytospins 1*10 6 PBMCs per patient were analyzed...
3030 Background: The clinical and immunologic efficacy of the optimized peptide TERT572Y (Vx-001) presented by HLA- A*0201 in patients with advanced malignancies was investigated. Methods: In context an expanded phase I-II study, 71 solid tumors (breast cancer n=10; NSCLC n=11; prostate mCRC n=2; RCC n=6; pancreatic cancer/cholangiocarcinoma n=14; melanoma n=8; HCC n=3; others n=7) who had been previously treated standard chemotherapy (disease status at enrollment: stable disease n=21...
Abstract In our previous study, high levels of one granulocytic (G-MDSC) and two monocytic (M-MDSCs) subpopulations immunosuppressive MDSCs were found their overexpression was correlated with worse prognosis in NSCLC patients. Using flow cytometry, the impact chemotherapy on percentages functionality M-MDSC (CD14+CD15-CD11b+CD33+HLA-DR-Lin- CD14+CD15+CD11b+ CD33+HLA-DR-Lin-) G-MDSC (CD14-CD15+CD11b+CD33+HLA-DR-Lin-) evaluated peripheral blood patients (n=141) prior to after 3rd 6th cycle...
17069 Background: BTERT 572Y , an optimized cryptic peptide homologous to TERT induces efficient antitumoral T cell cytotoxic immunity but not autoreactivity in vivo HLA-A*0201 transgenic mice and healthy blood donors prostate cancer patients (J. Clin. Invest., 2004, 113,425). Moreover, it was well tolerated effective eliciting specific (pts) with advanced malignancies (ASCO 2005, abstr 2579). Methods: We evaluated its clinical efficacy, safety immunogenicity 13 pts advanced, stage IIIb (7...